

## REFERENCES

1. Richelson E: Receptor pharmacology of neuroleptics: relation to clinical effects. *J Clin Psychiatry* 60 (Suppl 10): 5, 1999. [PMID: 10340682]
2. Thronson LR, Pagalilauan GL: Psychopharmacology. *Med Clin North Am* 98: 927, 2014. [PMID: 25134867]
3. Nandra KS, Agius M: The differences between typical and atypical antipsychotics: the effects on neurogenesis. *Psychiatr Danub* 24: S95, 2012. [PMID: 22945197]
4. Kusumi I, Boku S, Takahashi Y: Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. *Psychiatry Clin Neurosci* 69: 243, 2015. [PMID: 25296946]
5. Page CB, Calver LA, Isbister GK: Risperidone overdose causes extrapyramidal effects but not cardiac toxicity. *J Clin Psychopharmacol* 30: 387, 2010. [PMID: 20631557]
6. Levine M, Ruha AM: Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. *CNS Drugs* 26: 601, 2012. [PMID: 22668123]
7. Minns AB, Clark RF: Toxicology and overdose of atypical antipsychotics. *J Emerg Med* 43: 906, 2012. [PMID: 22555052]
8. Rauber-Lüthy C, Hofer KE, Bodmer M, et al: Gastric pharmacobezoars in quetiapine extended-release overdose: a case series. *Clin Toxicol (Phila)* 51: 937, 2013. [PMID: 24199644]
9. Miura N, Saito T, Taira T, Umehachi R, Inokuchi S: Risk factors for QT prolongation associated with acute psychotropic drug overdose. *Am J Emerg Med* 33: 142, 2015. [PMID: 25445869]
10. Berling I, Isbister GK: Prolonged QT risk assessment in antipsychotic overdose using the QT nomogram. *Ann Emerg Med* 66: 154, 2015. [PMID: 25639523]
11. Tan HH, Hoppe J, Heard K: A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. *Am J Emerg Med* 27: 607, 2009. [PMID: 19497468]
12. Isbister GK, Balit CR, Macleod D, Duffull SB: Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. *J Clin Psychopharmacol* 30: 391, 2010. [PMID: 20531221]
13. Nielsen J, Graff C, Kanters JK, et al: Assessing QT interval prolongation and its associated risks with antipsychotics. *CNS Drugs* 25: 473, 2011. [PMID: 21649448]
14. Joy JP, Coulter CV, Duffull SB, Isbister GK: Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses. *Clin Pharmacol Ther* 90: 243, 2011. [PMID: 21716272]
15. Gupta A, Lawrence AT, Krishnan K, et al: Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. *Am Heart J* 153: 891, 2007. [PMID: 17540188]
16. Coughlin DJ, Erdman AR, Booz LL, et al: Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. *Clin Toxicol (Phila)* 45: 918, 2007. [PMID: 18163235]
17. Borg L, Julkunen A, Rørbaek Madsen K, Strøm T, Toft P: Antidepressant or antipsychotic overdose in the intensive care unit: identification of patients at risk. *Basic Clin Pharmacol Toxicol* 119: 110, 2016. [PMID: 26663682]
18. Zemrak WR, Kenna GA: Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. *Am J Health Syst Pharm* 65: 1029, 2008. [PMID: 18499875]
19. Erickson SC, Le L, Zakharyan A, et al: New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. *J Am Geriatr Soc* 60: 474, 2012. [PMID: 22288652]
20. Lipscombe LL, Lévesque LE, Gruneir A, et al: Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. *Am J Geriatr Psychiatry* 19: 1026, 2011. [PMID: 22123274]
21. Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ: Atypical antipsychotics and diabetic ketoacidosis: a review. *Psychopharmacology (Berl)* 226: 1, 2013. [PMID: 23344556]
22. Galling B, Correll CU: Do antipsychotics increase diabetes risk in children and adolescents? *Expert Opin Drug Saf* 5: 1, 2014. [PMID: 25480466]
23. Sedky K, Lippmann S: Psychotropic medications and leukopenia. *Curr Drug Targets* 7: 1191, 2006. [PMID: 17017894]
24. Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. *Hum Psychopharmacol* 23 (Suppl 1): 15, 2008. [PMID: 18098213]
25. Hedges D, Juppson K, Whitehead P: Antipsychotic medication and seizures: a review. *Drugs Today (Barc)* 39: 551, 2003. [PMID: 12973403]
26. Lertxundi U, Hernandez R, Medrano J, et al: Antipsychotics and seizures: higher risk with atypicals? *Seizure* 22: 141, 2013. [PMID: 23146619]
27. Strawn JR, Keck PE, Caroff SN: Neuroleptic malignant syndrome. *Am J Psychiatry* 164: 870, 2007. [PMID: 17541044]
28. Berman BD: Neuroleptic malignant syndrome: a review for neurohospitalists. *Neurohospitalist* 1: 41, 2011. [PMID: 23983836]
29. Ware MR, Feller DB, Hall KL: Neuroleptic malignant syndrome: diagnosis and management. *Prim Care Companion CNS Disord* 20: 17r02185, 2018. [PMID: 29325237]
30. Croarkin PE, Emslie GJ, Mayes T: Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. *J Clin Psychiatry* 69: 1157, 2008. [PMID: 18572981]
31. Trollor JN, Chen X, Sachdev PS: Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. *CNS Drugs* 23: 477, 2009. [PMID: 19480467]
32. Ware MR, Feller DB, Hall KL: Neuroleptic malignant syndrome diagnosis frequency. *Acta Psychiatr Scand* 135: 398, 2017. [PMID: 28144982]
33. Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. *J Clin Psychiatry* 72: 1222, 2011. [PMID: 21733489]
34. Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN: A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. *J Clin Psychopharmacol* 37: 67, 2017. [PMID: 28027111]
35. Perry PJ, Wilborn CA: Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. *Ann Clin Psychiatry* 24: 155, 2012. [PMID: 22563571]
36. Sarkar S, Gupta N: Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. *BJPsych Bull* 41: 211, 2017. [PMID: 28811916]
37. Paden MS, Franjic L, Halcomb SE: Hyperthermia caused by drug interactions and adverse reactions. *Emerg Med Clin North Am* 31: 1035, 2013. [PMID: 24176477]
38. Musselman ME, Saely S: Diagnosis and treatment of drug-induced hyperthermia. *Am J Health Syst Pharm* 70: 34, 2013. [PMID: 23261898]
39. Pileggi DJ, Cook AM: Neuroleptic malignant syndrome. *Ann Pharmacother* 50: 973, 2016. [PMID: 27423483]
40. Neuhut R, Lindenmayer JP, Silva R: Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. *J Child Adolesc Psychopharmacol* 19: 415, 2009. [PMID: 19702493]